Improving treatment for tuberculosis and other mycobacterial infections
Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based Approach
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-10986101
This study is looking at ways to make tuberculosis and nontuberculous mycobacterial infections easier to treat by improving current antibiotics and adding new ones, so patients can have better and safer treatment options that fit their needs.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10986101 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections by optimizing existing antibiotics and integrating new drugs. It aims to address challenges such as drug resistance, toxicity, and the need for prolonged antibiotic use. By applying clinical pharmacology tools, the research will investigate how drug exposure relates to treatment outcomes, potentially leading to more effective therapies. Patients may benefit from improved treatment protocols that are tailored to their specific needs.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis or nontuberculous mycobacterial infections who require antibiotic treatment.
Not a fit: Patients with mycobacterial infections who are not undergoing antibiotic treatment or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients suffering from TB and NTM infections.
How similar studies have performed: Previous research has shown promise in optimizing antibiotic therapies for mycobacterial infections, indicating that this approach could yield significant advancements.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: IGNATIUS, ELISA HELEN — JOHNS HOPKINS UNIVERSITY
- Study coordinator: IGNATIUS, ELISA HELEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.